Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage

Transfusion

Volumn 57, Issue 5, 2017, Pages 1218-1225

  Cancelas, Jose A ^a   Slichter, Sherrill J ^b,c   Rugg, Neeta ^a   Pratt, P Gayle ^a   Nestheide, Shawnagay ^a   Corson, Jill ^b   Pellham, Esther ^b   Huntington, Marty ^d   Goodrich, Raymond P ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BloodWorks Northwest   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Terumo BCT   (United States)

^e Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; RIBOFLAVIN; TECHNETIUM 99M;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE PRESERVATION; FEMALE; HEMOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MULTICENTER STUDY; NORMAL HUMAN; PATHOGEN REDUCTION SYSTEM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ULTRAVIOLET RADIATION; BLOOD; BLOOD SAFETY; BLOOD STORAGE; CELL SURVIVAL; CLINICAL TRIAL; CYTOLOGY; DISINFECTION; DRUG EFFECTS; PROCEDURES; RADIATION RESPONSE;

ADULT; BLOOD; BLOOD PRESERVATION; BLOOD SAFETY; CELL SURVIVAL; CROSS-OVER STUDIES; DISINFECTION; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; MALE; PROSPECTIVE STUDIES; RIBOFLAVIN; SINGLE-BLIND METHOD; ULTRAVIOLET RAYS;

EID: 85017346266     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14084     Document Type: Article

References (43)

1. Marano G, Pupella S, Vaglio S, et al. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. Blood Transfus 2016;14:95-100.
2. Irsch J, Seghatchian J. Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects. Transfus Apher Sci 2015;52:240-4.
3. Bost V, Chavarin P, Boussoulade F, et al. Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept ™) over a 5-year period of extensive delivery. Vox Sang 2015;109:414-6.
4. Larrea L, Ortiz-de-Salazar MI, Martinez P, et al. Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies. Transfus Apher Sci 2015;52:305-10.
5. Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011;38:65-70.
6. Kwon SY, Kim IS, Bae JE, et al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014;107:254-60.
7. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005;45:1739-49.
8. Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011;51:2367-76.
9. North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011;51:2208-18.
10. Cancelas JA, Gottschall JL, Rugg N, et al. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017;112:210–8.
11. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
12. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
13. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010;38:20-30.
14. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011;51:1460-8.
15. Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.
16. Martin CB, Wilfong E, Ruane P, et al. An action spectrum of the riboflavin-photosensitized inactivation of Lambda phage. Photochem Photobiol 2005;81:474-80.
17. Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock 2015;44Suppl 1:33-8.
18. Schubert P, Culibrk B, Karwal S, et al. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion 2014;55:815-23.
19. Tonnetti L, Thorp AM, Reddy HL, et al. Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2015;55:326-9.
20. El Chaar M, Atwal S, Freimanis GL, et al. Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013;53:3174-83.
21. Reddy HL, Doane SK, Keil SD, et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013;53Suppl 1:131S-6S.
22. Tonnetti L, Thorp AM, Reddy HL, et al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013;53:860-7.
23. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012;52:409-16.
24. Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013;53:373-81.
25. Cancelas JA, Rugg N, Pratt PG, et al. Red cells from riboflavin plus UV-light treated whole blood can be effectively radiolabeled with 51-Cr for viability studies. Transfusion 2009;49:108A(S144).
26. Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 2015;372:1419-29.
27. AuBuchon JP, Cancelas JA, Herschel L, et al. In vitro and in vivo evaluation of LEUKOSEP HRC-600-C leukoreduction filtration system for red cells. Transfusion 2006;46:1311-5.
28. Usry RT, Moore GL, Manalo FW. Morphology of stored, rejuvenated human erythrocytes. Vox Sang 1975;28:176-83.
29. Moroff G, Sohmer PR, Button LN. Proposed standardization of methods for determining the 24-hour survival of stored red cells. Transfusion 1984;24:109-14.
30. Recommended method for radioisotope red-cell survival studies. International Committee for Standardization in Haematology. Br J Haematol 1980;45:659-66.
31. Marsh WL, Jenkins WJ. Anti-i: a new cold antibody. Nature 1960;188:753.
32. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion 2002;42:146-52.
33. Rios JA, Hambleton J, Viele M, et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006;46:1778-86.
34. Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second generation S-303 pathogen inactivation process. Transfusion 2011;51:2367-76.
35. Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010;38:14-9.
36. Dumont LJ, AuBuchon JP. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials. Transfusion 2008;48:1053-60.
37. Maia GA, Cortes VF, Ribeiro RI, et al. Could Na,K-ATPase play a role in potassium leakage from irradiated erythrocytes? Clin Chim Acta 2014;433:58-61.
38. Brugnara C, Churchill WH. Effect of irradiation on red cell cation content and transport. Transfusion 1992;32:246-52.
39. Moroff G, Holme S, AuBuchon JP, et al. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999;39:128-34.
40. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471-82.
41. Novak DJ, Bai Y, Cooke RK, et al. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion 2015;55:1331-9.
42. Agapova M, Lachert E, Brojer E, et al. Introducing pathogen reduction technology in Poland: a cost-utility analysis. Transfus Med Hemother 2015;42:158-65.
43. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.